Cameron Turtle, Chief Executive Officer at Spyre Therapeutics, Inc. (SYRE), sold 15,000 shares at $69.54 ($1.1M) on 2026-05-01, disclosed to the SEC on 2026-05-01.
Scheduled sale ($1.1M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $69.54 | 5,300 | $369K | 34.4% |
| 2 | $70.77 | 3,600 | $255K | 23.8% |
| 3 | $71.76 | 1,000 | $72K | 6.7% |
| 4 | $73.14 | 3,100 | $227K | 21.2% |
| 5 | $74.23 | 1,700 | $126K | 11.8% |
| 6 | $74.96 | 300 |
| $22K |
| 2.1% |
| Total | $71.37 avg | 15,000 | $1.1M | 100% |
| Filing → |
| SYRE | SELL | 2026-08-05 | $1.4M | — | Filing → |
| SYRE | SELL | 2026-07-02 | $1.3M | — | Filing → |
| SYRE | SELL | 2026-06-03 | $1.1M | — | Filing → |